Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress

The ability of the Cav1 channel inhibitor isradipine to slow the loss of substantia nigra pars compacta (SNc) dopaminergic (DA) neurons and the progression of Parkinson’s disease (PD) is being tested in a phase 3 human clinical trial. But it is unclear whether and how chronic isradipine treatment wi...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Guzman, Jaime N., Ilijic, Ema, Yang, Ben, Sanchez-Padilla, Javier, Wokosin, David, Galtieri, Dan, Kondapalli, Jyothisri, Schumacker, Paul T., Surmeier, D. James
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5983329/
https://ncbi.nlm.nih.gov/pubmed/29708514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI95898
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars